Bone Biologics Corp Cash Flow Conversion Efficiency
Bone Biologics Corp cash flow conversion efficiency. Based on the latest financial reports, Bone Biologics Corp (BBLG) has a cash flow conversion efficiency ratio of -0.132x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-518.44K) by net assets ($3.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Bone Biologics Corp (2012–2025)
Cash flow conversion efficiency of Bone Biologics Corp from 2012 to 2025. This chart illustrates how Bone Biologics Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Bone Biologics Corp for real-time trading data and today's change.
Bone Biologics Corp Cash Flow Conversion Ratio Explained
Bone Biologics Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Bone Biologics Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bone Biologics Corp ranked by their cash flow conversion efficiency. Also see market cap of Bone Biologics Corp for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BAKED GAMES SA ZY-10
F:4U6
|
-0.113x |
|
Total Helium Ltd
V:TOH
|
0.006x |
|
Intercede Group
LSE:IGP
|
0.100x |
|
Rapid Nutrition PLC
PA:ALRPD
|
-1.217x |
|
Avation PLC
LSE:AVAP
|
-0.005x |
|
Edri-El
TA:EDRL
|
0.013x |
|
Gentlemens Equity S.A.
PA:MLGEQ
|
N/A |
|
Anpario Plc
LSE:ANP
|
0.112x |
Annual Cash Flow Conversion Efficiency for Bone Biologics Corp (2012–2025)
The table below shows the annual cash flow conversion efficiency of Bone Biologics Corp from 2012 to 2025. Review BBLG free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.38 Million | $-2.69 Million | -0.500x | +57.74% |
| 2024-12-31 | $3.48 Million | $-4.12 Million | -1.184x | +63.99% |
| 2023-12-31 | $2.91 Million | $-9.56 Million | -3.288x | -448.21% |
| 2022-12-31 | $5.95 Million | $-3.57 Million | -0.600x | -220.99% |
| 2021-12-31 | $6.58 Million | $-1.23 Million | -0.187x | -699.23% |
| 2020-12-31 | $-13.69 Million | $-426.93K | 0.031x | -88.62% |
| 2019-12-31 | $-11.87 Million | $-3.25 Million | 0.274x | -42.62% |
| 2018-12-31 | $-8.60 Million | $-4.10 Million | 0.477x | +20.37% |
| 2017-12-31 | $-8.40 Million | $-3.33 Million | 0.397x | -53.27% |
| 2016-12-31 | $-8.63 Million | $-7.33 Million | 0.849x | +35.98% |
| 2015-12-31 | $-5.68 Million | $-3.55 Million | 0.624x | -16.23% |
| 2014-12-31 | $-3.70 Million | $-2.76 Million | 0.745x | +68218.73% |
| 2013-12-31 | $-5.61 Million | $-6.12K | 0.001x | -98.86% |
| 2012-12-31 | $-4.68K | $-447.00 | 0.096x | -- |
About Bone Biologics Corp
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, a… Read more